Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Sept. 2, 2025 /CNW/ -- Cancer innovation is reaching new heights as the FDA approved breakthrough therapies for aggressive malignancies, including Modeyso for deadly brain tumors, while breakthrough designations accelerate for next-generation therapies targeting previously resistant cancers. This regulatory momentum builds upon a wave of July breakthrough designations and regulatory milestones spanning multiple cancer types. The expanding regulatory support is generating substantial opportunities for companies with cutting-edge oncology platforms to leverage expedited approval pathways, including Oncolytics Biotech Inc. (NASDAQ:ONCY), NeoGenomics, Inc. (NASDAQ:NEO), Guardant Health, Inc. (NASDAQ:GH), Cellectar Biosciences, Inc. (NASDAQ:CLRB), and Zai Lab Limited (NASDAQ:ZLAB).
Read more at newswire.ca
/A%20Lucid%20Motors%20vehicle%20parked%20in%20front%20of%20a%20showroom_%20Image%20by%20Michael%20Berlfein%20via%20Shutterstock_.jpg)
/Broadcom%20Inc%20logo%20on%20phone%20and%20site-by%20Majahid%20Mottakin%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)
